| Description | (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats. |
| In vivo | Diabetic rats were administered myrtenal (80 mg/kg bw) for a period of 28 days. Diabetic rats showed an increased the levels of plasma glucose, decreased the levels of plasma insulin, down-regulation of insulin receptor substrate 2 (IRS2), Akt and glucose transporter 2 (GLUT2) in liver and insulin receptor substrate 2 (IRS2), Akt and glucose transporter 4 (GLUT4) protein expression in skeletal muscle[1]. |
| Synonyms | (1R)-(-)-桃金娘烯醛, 桃金娘烯醛, (1R)-(−)-Myrtenal |
| molecular weight | 150.22 |
| Molecular formula | C10H14O |
| CAS | 18486-69-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (199.71 mM) |
| References | 1. Rathinam A , Pari L . Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats[J]. Chemico-Biological Interactions, 2016:S0009279716302836. 2. Rathinam A , Pari L , Venkatesan M , et al. Myrtenal attenuates oxidative stress and inflammation in a rat model of streptozotocin-induced diabetes[J]. |